



Cite this: *RSC Chem. Biol.*, 2022, 3, 407

Received 12th January 2022,
Accepted 16th February 2022

DOI: 10.1039/d2cb00007e

rsc.li/rsc-chembio

Recent advances in DNA-encoded dynamic libraries

Bingbing Shi,^a Yu Zhou*^b and Xiaoyu Li *^{bc}

The DNA-encoded chemical library (DEL) has emerged as a powerful technology platform in drug discovery and is also gaining momentum in academic research. The rapid development of DNA-/DEL-compatible chemistries has greatly expanded the chemical space accessible to DELs. DEL technology has been widely adopted in the pharmaceutical industry and a number of clinical drug candidates have been identified from DEL selections. Recent innovations have combined DELs with other legacy and emerging techniques. Among them, the DNA-encoded dynamic library (DEDL) introduces DNA encoding into the classic dynamic combinatorial libraries (DCLs) and also integrates the principle of fragment-based drug discovery (FBDD), making DEDL a novel approach with distinct features from static DELs. In this Review, we provide a summary of the recently developed DEDL methods and their applications. Future developments in DEDLs are expected to extend the application scope of DELs to complex biological systems with unique ligand-discovery capabilities.

1. Introduction

1.1 DNA-encoded chemical library (DEL)

The identification of small-molecule ligands that can modulate the functions of biological targets is central to chemical, biological, and pharmaceutical sciences. For decades, high-

throughput screening (HTS) has been a major ligand-discovery modality;¹ however, HTS platforms are complex, prohibitively expensive, and are limited to several millions of compounds. In the past two decades, the emergence of the DNA-encoded library (DEL) technology, also called DELT, has replaced spatial encoding with DNA encoding in chemical libraries, thus overcoming the throughput limit of traditional HTS and being much more affordable and accessible to researchers.^{2–11} For instance, many companies and institutions are offering DEL selection services: premade DEL kits¹² for direct use in selections, and reagent kits¹³ for custom DEL synthesis are also available to meet the needs of individual researchers. Furthermore, with the recent expansion of DNA-/DEL-compatible reaction toolkits,^{2,6,7,14–16} DELs can access much greater chemical space, which has

^a Department of Biochemistry and Molecular Biology, College of Basic Medicine, Jining Medical University, Jining, Shandong 272067, P. R. China

^b Department of Chemistry and State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, China.
E-mail: yuchow@hku.hk, xiaoyuli@hku.hk

^c Laboratory for Synthetic Chemistry and Chemical Biology Limited, Health@InnoHK, Innovation and Technology Commission, Units 1503-1511, 15/F., Building 17W, Hong Kong SAR, China



Bingbing Shi

Dr Bingbing Shi received her BS degree from Minzu University of China in 2013 and her PhD degree in Chemistry from Peking University in 2018 under the supervision of Prof. Xiaoyu Li. She is currently an Associate Professor at Jining Medical University. Her research interests lie in drug discovery and clinical oncology.



Yu Zhou

Dr Yu Zhou received his BS degree from Minzu University of China in 2014 and his PhD degree in Chemistry from Peking University in 2019. He is currently a postdoctoral fellow at The University of Hong Kong. His research is focused on the development of new methods for DNA-encoded libraries and their applications in drug discovery.



been a major driver for its adoption in the pharmaceutical industry.^{3,11,17–20}

The concept of the DEL was proposed by Brenner and Lerner in 1992.²¹ It was originally devised as an approach to improve the traditional one-bead, one-compound (OBOC) combinatorial chemical library by synthesizing an on-bead DNA tag along with the compound. After the screening, the DNA-tagged OBOC library (OBOC-DEL) could be deconvoluted by reading the DNA sequence attached to the isolated beads. The concept was quickly realized by Nielsen, Brenner, and Janda²² as well as by Gallop and co-workers in 1993.²³ OBOC-DELS had a practical limit on the library size (*e.g.*, the number of beads that can be handled) and involved the challenging parallel synthesis of chemical compounds and oligonucleotides. Nevertheless, these early studies laid out the technological foundation of DELs, including the encoding strategy, selection method, and decoding techniques. Later, OBOC-DELS became less reported, and until recently, the research groups of Paegel and Kodadek have revived OBOC-DELS with sophisticated bead designs, novel on-bead chemistry, and advanced instrumentation, which have led to a variety of novel applications.^{7,15,23–29} The details of modern OBOC-DELS fall outside the scope of this review and we refer interested readers to these excellent review articles.^{9,30,31} In 2004, Neri,³² Liu,³³ Harbury,³⁴ Winssinger,³⁵ and their respective co-workers independently reported four types of encoded library: the dual-pharmacophore encoded self-assembling chemical (ESAC) library, the DNA-templated synthesis (DTS) library, the DNA-routing library, and the peptide–nucleic-acid (PNA)-encoded library. The libraries are encoded by either DNA translation, routing, or ligation in the solution phase, thereby overcoming the limitations of OBOC libraries. In a seminal work in 2009, GlaxoSmithKline (GSK) demonstrated the application of DELs at an industrial scale.³⁶ Following these landmark studies, DELs entered a stage of rapid developments. The declining cost of genomic-scale next-generation sequencing (NGS) technologies has made the selection of multi-billion-compound DELs a routine practice. With the rapid development of DEL-compatible chemistry,




Fig. 1 Schematic illustrations of (a) the selection of a DNA-encoded library (DEL) against immobilized protein targets and (b) the formation and selection of a dynamic combinatorial library (DCL).

arguably, the chemical space of DELs is limited by the availability of the building blocks, rather than the reactions to connect them.^{2,7} Recent innovations have also integrated DEL with many legacy and emerging techniques, such as fragment-based drug discovery (FBDD),^{32,37–40} the dynamic combinatorial library (DCL),^{41–47} diversity-oriented synthesis (DOS),^{48,49} machine learning,^{50–52} OBOC libraries/microfluidics,^{24,26,53–55} flow cytometry,^{23,27,28} *etc.*, leading to novel applications in ligand discovery and functional assays.^{9,30} DEL selections have generated a number of clinical candidates,¹⁷ such as GSK2256294, an epoxide hydrolase inhibitor to treat pulmonary disease,^{17,18} GSK2982772, a first-in-class receptor-interacting protein-1 kinase inhibitor to treat inflammatory diseases,^{17,19} and X-165, an autotaxin inhibitor as the clinical candidate for pulmonary fibrosis.²⁰ Very recently, researchers selected a 4-billion DEL against the SARS-CoV-2 main protease (M^{pro}) and obtained potent inhibitors with high potential for clinical development.⁵⁶

Regardless of whether in solution or on beads, most DELs are “static”, *i.e.*, the population of the library is fixed. Incubation with the target establishes a thermodynamic equilibrium, which is usually driven by the high concentration of the protein (0.4–50 μM),⁸ and a series of washing steps to remove the non-binders, whereas the “enriched” binders are eluted under denaturing conditions (Fig. 1a). The ideal condition for affinity-based DEL selections should be a balance of the thermodynamic association (K_a) and kinetic disassociation (k_{off}) parameters. However, first, developing an optimal washing protocol is rather difficult as many factors are implicated (the number of washes, time duration, buffers, centrifugation conditions, temperature, *etc.*). The Neri group provided an excellent protocol as a reference for DEL selections,⁵⁷ and recent studies have shown that quantitative PCR (qPCR) is an effective tool for quality control.^{58–62} Second, the binders with low abundance may be missed if their copy numbers fall below the detection threshold after the selection,^{59,63} which may worsen for very large libraries. Third, the washing-based selections require a purified and immobilized protein, which may limit the target scope. Recent studies have developed several methods for in-solution DEL selections in buffers, in cell lysates, on/within live cells, with whole bacteria, and even in human sera.⁸ However, DEL selections with immobilized targets remain the mainstream practice.



Xiaoyu Li

Dr Xiaoyu Li received his BS degree from Peking University in 1997 and his PhD degree in 2002 from the University of Chicago. After a postdoctoral training at Harvard University, he conducted research in several biotech firms. In 2009, he joined Peking University as an Associate Professor, and in 2015 Dr Li joined The University of Hong Kong and is currently a Professor at the Department of Chemistry.

Dr Li's research focuses on DNA-encoded chemical libraries, protein labelling and profiling, and target identification.



1.2 Dynamic combinatorial library (DCL)

The dynamic combinatorial library (DCL) is a type of combinatorial chemical library, where the library is formed *in situ* by mixing the building blocks (BBs) that can undergo dynamic exchange through reversible chemical reactions (Fig. 1b).^{64–78} In contrast to traditional HTS and DEL selection, DCL screening utilizes the protein to template the ligand synthesis. Compared with a static library, first, the DCL allows for the spontaneous formation of the binders without spatial separation; second, the DCL has the advantage of high-affinity but low-abundance binders being amplified from a large excess of a non-binding background, *i.e.*, a higher signal-to-noise ratio; third, DCLs can be feasibly prepared by mixing the BBs (also called fragments) in a single solution without the synthesis of individual compounds; fourth, DCLs are under thermodynamic control, and a comparison of the equilibria before and after target addition is able to identify the binders. In the past decades, DCLs have shown great potential in drug discovery, materials science, and systems chemistry. However, the development and application of DCLs have been significantly hampered by the small library size.

Although elegant strategies have been developed to access large dynamic libraries,^{79–84} most DCLs only contain a few dozen to several hundreds of compounds.⁶⁸ The major underlying reason is the lack of analytical methods suitable for resolving large libraries and identifying the binders from complex mixtures.^{68,78,85,86} Typically, liquid chromatography,^{68,87–91} mass spectrometry,⁹² NMR,⁹³ and spectroscopic methods^{81,94,95} are used for hit identification in DCL screening, but these methods lack the resolution and throughput for large libraries. In addition, DCL screening usually requires high protein consumption and involves tedious sample-processing procedures (*e.g.*, the separation of protein from bound ligands prior to analysis).

1.3 Concept and advantages of the DNA-encoded dynamic library (DEDL)

The DCL and the DEL share some similarities in that both are “one-pot” libraries and all the compounds are synthesized, processed, and selected simultaneously without spatial separation. However, DELs can contain a very large number of compounds and




Fig. 2 Schematic illustrations for (a) selection of the dual-pharmacophore ESAC library, (b) the tag-transfer strategy to connect the two sets of codes in ESAC libraries, (c) assembly and selection of the PNA-encoded, DNA-templated fragment library, and (d) the original concept of the dynamic assembly of DNA-encoded fragments.



the library selection can be conducted at a minute scale. Hence, introducing DNA encoding may be a promising strategy to address the long-lasting issue of DCLs. On the other hand, dynamic DELs have the advantages of DCLs. The preparation of dynamic DELs is straightforward by simply mixing the DNA-encoded BBs. The protein target can act as the template to promote the synthesis/enrichment of the binders, which may give a higher signal-to-noise ratio and enable the identification of the high-affinity binders with copy numbers below the reliability threshold in DEL selections (10^3 – 10^4 copies per compound).^{59,63} Furthermore, the selection of dynamic DELs may be conducted without physical washes, thus realizing selections in solution or with complex biological targets. Indeed, researchers have developed a number of dynamic DEL approaches.⁹⁶ Although these methods are given different names in different studies, to avoid confusion, they are generally referred as DNA-encoded dynamic libraries (DEDLs) in this Review Article.

2. Previous studies leading to the development of DEDLs

2.1 Dual-pharmacophore ESAC library

In 2004, the Neri group reported an encoded self-assembling chemical (ESAC) library method in which two sets of partially complementary DNA-encoded BBs are mixed to form a combinatorial library of fragments (Fig. 2a).^{32,37,97–102} The library is selected against immobilized targets, and the binding BBs can be decoded by sequencing the coding regions. Initially, the two BBs in a binding pair are separately decoded and their correlation is lost; thus, ESAC libraries were mostly used for affinity maturation of known ligands.^{98,99,103} Recently, an elegant tag-transfer approach was developed to incorporate both sets of codes into one DNA strand (Fig. 2b),³⁷ so that the synergistic BB pairs, instead of individual BBs, could be identified. ESAC libraries have been successfully employed to discover novel ligands against a variety of biological targets.¹⁰⁴ The quality of ESAC libraries is very high, since each DNA-conjugated BB is chromatographically purified and there are no truncated/side products as in regular DELs.^{105–107} In principle, the ESAC library is in line with fragment-based drug discovery (FBDD), where small fragments (*i.e.*, the BBs) that cooperatively bind to the target are identified before being elaborated into high-affinity binders through fragment linking, growing, and/or merging.⁸⁵ However, ESAC libraries are static and are usually selected against purified and immobilized proteins.

2.2 PNA/DNA-directed fragment assembly

PNA (peptide nucleic acid) is a type of nucleic acid that can form duplexes with DNA, RNA, and the PNA itself with a neutral and achiral peptidic backbone. PNA also has a coding system of four canonical bases, but it is more chemically stable and compatible with organic reactions. Previously, PNA has been extensively used to encode small-molecule probes in proteomic profiling, combinatorial libraries, and ligand displays.^{108–113}

However, PNA is not compatible with PCR amplification and DNA sequencing technologies. Winssinger and co-workers developed an elegant strategy combining the advantages of DNA and PNA.^{39,114} As shown in Fig. 2c, two sets of PNA-encoded fragments are assembled on DNA templates, forming a fragment-pair library. After the selection, the DNA templates of the selected fragment pairs are amplified *via* PCR and then re-translated into a more focused fragment library for more rounds of selection. Although these PNA/DNA-encoded libraries were also static, as suggested by the authors, this approach may provide a viable encoding strategy for DCLs.³⁹

2.3 Dynamic DNA ligand assemblies

Beyond duplexes, higher dimensions of fragment assemblies have been constructed with DNA triplexes,^{32,115,116} quadruplexes,^{117–121} or even pentaplex structures.¹²² The first report on using DNA duplexes to *dynamically* display small molecules was by the Hamilton group in 2005.¹²³ As shown in Fig. 2d, they prepared a 9-member library assembled from two sets of DNA-encoded small molecules containing an iminobiotin, a methyl adipate, and an amino group. The library was exposed to an immobilized streptavidin (SA), a homo-tetrameric protein that can bind to four biotin or biotin derivatives with four binding pockets. Without heating, the library was static (analogous to an ESAC library), and the selection identified both the monodentate and bidentate biotin duplexes. After the library was heated above the melting temperature of the DNA duplexes, the library became dynamic and started exchanging DNA strands, and the selection with SA identified the enrichment of the high-affinity bidentate iminobiotin duplexes. This study has demonstrated that, in a dynamic DNA display, the protein can promote the formation of high-affinity duplex binders at the expense of the non-binders and the moderate binders. This work has established the basic principle for the future development of DEDLs.

3. Development of DEDLs

3.1 DNA-encoded dynamic combinatorial chemical library (EDCCL)

The first DEDL method was reported by Zhang and co-workers in 2015, and was named the DNA-encoded dynamic combinatorial chemical library (EDCCL).⁴¹ As shown in Fig. 3a, first, an ESAC-type library with stable DNA duplexes was formed. After the first round of selection with an immobilized target, the flow-through was heated to melt the DNA duplexes and enable the dynamic exchange of the DNA strands. Such a reshuffling process promoted the formation of more high-affinity duplexes, which can be further enriched in more rounds of selection. Several model libraries were prepared by mixing different ratios of the non-binding DNA duplexes and the duplexes with an iminobiotin. The authors also tested different numbers (*m*) of complementary base pairs to adjust the duplex stability. When *m* is large (*e.g.*, *m* = 21), the duplexes were stable, and the library was static. The selection with SA did enrich the high-affinity bidentate iminobiotin duplexes, but the enrichment fold was low due to






Fig. 3 Schematic illustrations for the (a) EDCCL/hi-EDCCL and (b) Y-EDCCL approaches.

the low reshuffling rate of the DNA duplexes, *i.e.*, a high kinetic barrier (Fig. 3a). When m was decreased to 6–8, the library became dynamic, and the addition of SA shifted the equilibrium and led to the enrichment of the bidentate duplexes. The enrichment of the dynamic library was more significant than the static library. Notably, the weaker the monovalent binding, the greater is the enrichment of the bidentate duplexes. The authors also showed that this method could identify low- to high-micromolar binders, a typical affinity range for unbiased DEL selections. Furthermore, this approach was extended to heat-induced EDCCLs (hi-EDCCLs), where the affinity selection and the heat-induced recombination process were carried out separately. As shown in Fig. 3a, after the selection of the stable library against the immobilized SA, the flow-through containing the non-binders and weak binders was subjected to a heating/annealing process to reshuffle the DNA strands and form more of the high-affinity bidentate duplexes. The reshuffled library was then subjected to more rounds of selection for further enrichment. EDCCL/hi-EDCCL was the first systematic study demonstrating the preparation and selection strategies of dynamic DELs. Although no chemical and sequence diversities were included in these model libraries, this study has shown that, in principle, DNA encoding could enable the selection of large DCLs, as the bidentate duplex was enriched from a 90 600-fold excess of the non-binding background.

The hi-EDCCL suffers the issue of strong heating (up to 90 °C), which may be detrimental to the protein and/or the compounds. In 2019, Zhang and co-workers improved the EDCCL method by using a Y-shaped DNA architecture (Y-EDCCL).⁴² As shown in Fig. 3b, the Y-EDCCL is assembled from two sets of partially complementary DNA-encoded BBs, and the short

hybridization region makes the dynamic assembly/reshuffling possible at room temperature. The selection of Y-EDCCLs was also conducted with an immobilized target, and the high-affinity duplexes bound to the target stabilized the Y-shaped DNA complex. The DNA codes of the two strands were enzymatically ligated for decoding (Fig. 3b). The ligation step may provide an additional mechanism for reducing the background arising from single BB binding since the corresponding DNA codes could not be ligated. Notably, the selection of Y-EDCCLs gave a significantly higher enrichment of the bidentate binders in comparison with either the Y-shaped or the linear static library (>26-fold higher enrichment in SA selection). Although only model libraries with a limited diversity were tested (a 285-member Y-EDCCL was selected against carbonic anhydrase II, CA-2), Y-EDCCL is compatible with the standard hit decoding scheme of DELs, suggesting that large DEDLs could be built and selected with this method. Collectively, these studies have nicely shown that DNA encoding can indeed be used to prepare, process, and select large dynamic libraries against proteins. In addition, the EDCCL has been adapted to an automated microfluidic platform with improved efficiency,¹²⁴ and the technology has also been commercialized and is being sold as a selection kit (DyNABind[®]) for fragment discovery.¹²

For DCL selections, after the equilibrium is shifted to a new state induced by the target, an equilibrium-locking procedure is carried out to stop the dynamic exchange, so that the “locked” equilibrium may be compared with that without target addition (or other controls) for hit identification. Equilibrium locking can be accomplished either by changing the experimental condition (*e.g.*, pH, temperature, or solvent composition) or by using additives (*e.g.*, using NaBH₃CN to reduce imine to amine or lowering the pH to stop disulfide exchange). Ideally, the “locking”



mechanism should be very fast or at least significantly faster than the dynamic BB exchange, so that the locking process itself has a minimal effect on the position of the equilibrium.^{65,66} In Hamilton's dynamic duplex display and EDCCL, there was no equilibrium locking, and the binders and non-binders were separated *via* washes off the immobilized targets. In the EDCCL, a model library was selected against non-immobilized SA using a selective digestion strategy,¹²⁵ but this was still a virtual washing procedure and nuclease digestion may perturb the equilibrium.⁶⁵ Hence, it is desirable to develop DEDL methods that can reliably lock the equilibrium after target addition, so that the dynamic libraries can be applied to more diverse types of biological target.

3.2 Photo-crosslinking-mediated selection of DEDLs

In 2015, the Li group reported a DEDL method using photo-crosslinking to lock the equilibrium.⁴³ As shown in Fig. 4a, a set

of DNA-encoded fragments is hybridized with an “anchor” DNA, which bears a known ligand for the target and a photo-crosslinker (psoralen) at the distal end of the DNA strand. When the DNA-encoded fragments are in excess, they compete for hybridization with the anchor DNA. Due to the short length (6–7 nt), the duplexes are unstable and constantly exchange DNA strands, thereby forming a DEDL of “fragment–anchor” pairs. Upon target addition, the equilibrium shifts to form more high-affinity bidentate duplexes. Next, the photo-reactive psoralen group crosslinks to the opposite DNA strand upon UV irradiation, which stops the dynamic exchange and locks the equilibrium. The crosslinked duplexes can be isolated for hit identification by reading the encoding DNA sequence (Fig. 4a). Notably, the photo-crosslinking step is very fast (30–60 s) and can be easily imposed/withdrawn without any additives and little perturbation to the equilibrium, *i.e.*, like taking a photo




Fig. 4 Schematic illustrations for the selection of DEDLs mediated by photo-crosslinking. (a) The early version uses an anchor DNA and a terminal psoralen photo-crosslinker to lock the shifted equilibrium after target addition. (b) The improved version may combinatorially assemble two sets of DNA-encoded fragments, and hit decoding is accomplished using relay-primer-bypass PCR. (c) Regular DELs could be adapted to a DEDL format. (d) DEDL for direct ligand identification without fragment linking.



snapshot. Although the efficiency of the photo-crosslinking reaction is low in aqueous solution, this was not a major issue because the crosslinked duplexes could be amplified *via* the highly sensitive PCR. Actually, this might be an advantage because of the low background signal arising from the non-binding duplexes. The authors have carefully verified that the system was under thermodynamic control, *i.e.*, different starting points led to the same thermodynamic equilibrium, which is an important feature of DCLs.^{126,127} Moreover, this method completely abolished protein modification/immobilization and physical washes. The selection takes place in one solution and is suitable for unmodified, non-immobilized proteins.^{125,128,129} This study selected a model library against SA and CA-2, and the SA selection gave a 19.2-fold enrichment of the bidentate desthiobiotin duplex, which is comparable to typical DCL selections.^{90,130–132} However, this approach can only be used for the “affinity maturation” of known ligands,^{32,37,97,98} rather than *de novo* discovery.

In 2018, the Li group made a major advancement on the photo-crosslinking-based DEDL method.⁴⁴ As shown in Fig. 4b, two sets of DNA-encoded fragments formed a combinatorial library of fragment pairs. Again, the short hybridization region resulted in dynamic exchange of the DNA strands, whereas the distal regions of the DNA strands were not complementary and contained the DNA codes. The hybridization region was also embedded with a pair of *p*-stilbazole molecules, an efficient inter-strand DNA photo-crosslinker orthogonal to natural nucleobases with little impact on the properties of the DNA duplexes.¹³³ After target incubation, UV irradiation crosslinked the duplexes and locked the equilibrium. The crosslinking resulted in an unnatural junction that is unreadable to DNA polymerase. To read the codes, a relay-primer-bypass decoding strategy was used.¹³⁴ In addition to the regular terminal primers, a relay primer was added to mask the unnatural linkage; polymerase-extension of the primers and enzymatic ligation generated a DNA template that is compatible with PCR amplification (Fig. 4b). A 10 000-member DEDL with actual chemical diversity was prepared and selected against four protein targets covering a range of protein families (SIRT3, SAE1, UBC9, and TRIM28). For each target, multiple fragment pairs were enriched, which were further conjugated with a series of linkers of different lengths, flexibilities, and lipophilicities.⁹⁸ In general, the shorter linkers or no linker (*i.e.*, direct conjugation of the fragments) gave more potent ligands/inhibitors. More recently, Li and co-workers selected the same DEDL against SIRT-1, -2, and -5, as well as the BD1 and BD2 domains of bromodomain (BRD4).¹³⁵ Despite the moderate library size, a series of isoform-/domain-selective ligands/inhibitors were identified. Collectively, these studies have demonstrated the generality and performance of chemically diverse DEDLs in *de novo* ligand discovery.

Typical DELs contain 3–4 sets of BBs; however, most DEDLs are built on DNA duplexes with two sets of BBs, which limits the library size. In addition, the DEDL shown in Fig. 4a requires a pair of unnatural photo-crosslinkers. It is more desirable that regular DELs can be adapted to a DEDL format without library resynthesis. In 2020, the Li group replaced the *p*-stilbazole with a psoralen group (Fig. 4c).¹³⁶ Psoralen can be conjugated to the

non-base-pairing side of the nucleobases in DNA, is commercially available, and does not require a crosslinking partner in the opposite strand. Thus, in principle, any DEL encoded with single-stranded DNA tags may be adapted to a DEDL and the common primer-binding site can be used for dynamic hybridization.












3.3 Non-fragment-based DNA-encoded dynamic library

All the DEDLs discussed above are fragment-based libraries; thus, they can only be used for the discovery of synergistic fragment pairs or affinity maturation of the known ligands.¹³⁷ A fragment-linking step is required to obtain the full ligands. In fact, fragment linking is a frequently used strategy to evolve fragments into high-affinity/high-specificity ligands.^{138–141} Ideally, the linked fragments should bind to the target more strongly than the sum of individual ones;^{142–144} however, the linker has profound effects on the binding properties.^{145–148} Previously, Seitz, Winssinger, Neri, and their respective co-workers have elegantly shown that small fragments selected from DELs or DNA-display libraries could be elaborated into potent binders by screening different linkers^{37,38,98,99,149–151} or using rigid scaffolds.¹⁴⁶ Nevertheless, fragment linking is still a tedious and empirical procedure with lots of trial-and-error.^{144,145} In fact, fragment linking takes considerably more effort than identifying the fragment itself and is a major issue in fragment-based ligand discovery.^{85,147,152}

Most DCLs are also fragment libraries; however, since the protein target templates the synthesis of the full ligands *in situ*, fragment linking is no longer necessary. In most DEDLs, there is no chemical reaction between the fragments and the dynamic interaction only takes place between the DNA strands. In 2020, the Li group partially addressed in the issue.⁴⁵ As shown in Fig. 4d, a regular DEL encoded with a single-stranded DNA tag bearing a primary amine is incubated with an “anchor”, which is a known ligand of the target with an aldehyde group. Imine formation *via* aldehyde–amine condensation is a widely used dynamic combinatorial chemistry (DCC) step in DCLs and is compatible with physiological conditions.⁷⁶ The dynamic imine library is selected against the non-immobilized target. The shifted equilibrium is locked by NaBH₃CN reduction to amines. The binders could be isolated from the mixture using an *N*-hydroxysuccinimide (NHS) ester, which has a lower activity for secondary amines. A more selective reagent, such as *o*-phthaldialdehyde (OPA),¹⁵³ may be used to improve the specificity. The anchor could be flexibly changed to convert an unbiased DEL to a focused one. Existing DELs prepared using other methods or encoded with double-stranded DNA tags may be used, as long as the library contains a primary amine. The method was tested with five proteins, *i.e.*, CA-2, BD1 and BD2 of BRD4, acetylcholinesterase (AChE), and the X-linked inhibitor of apoptosis protein (XIAP), and it identified the binders of a wide range of affinities (low-nM to mid- μ M). However, the molecular weight of the library compounds had significant effects on the selection results. The selection of a small, 2-BB library (67 000 compounds) identified many more potent and selective ligands than the



Table 1 Summary of the reported DEDLs and the dual-pharmacophore static DELs

	Library architecture	Selection method	Target(s)	Building block sets	Building blocks in each set	Size	Key reference(s)
ESAC library		Immobilized protein	Alpha-1-acid glycoprotein, carbonic anhydrase IX	2	550 members in sub-library A, 202 members in sub-library B	111 100	32,37 and 104
Dynamic assembly of DNA-encoded fragments		Immobilized protein	Streptavidin	1	3 × 3 model library with iminobiotin as positive control	9	123
EDCCL		Immobilized protein	Streptavidin	1	Model library with iminobiotin as positive control	90 601	41
Heat-induced EDCCLs		Unmodified, non-immobilized protein	Alpha-1-acid glycoprotein	1	Model library with furan derivatives as positive control	4001	41
Y-EDCCL		Immobilized protein	Streptavidin	1	Model library with iminobiotin as positive control	961	41
Y-EDCCL		Immobilized protein	Carbonic anhydrase II	1	285 members in sub-library A, and a positive control CBS on sub-library B	286	42
First version of the photo-crosslinking-based DEDL		Unmodified, non-immobilized proteins	Streptavidin, carbonic anhydrase II	1	Model library with desthiobiotin as positive control	1025	43
Second version of the photo-crosslinking-based DEDL		Unmodified, non-immobilized proteins	SIRT3, SAE1, UBC9, and TRIM28	2	100 members in each sub-library	10 000	44
Third version of the photo-crosslinking-based DEDL		Unmodified, non-immobilized proteins	Streptavidin	1	Model library with desthiobiotin as positive control	10 001	136
Anchor-directed DEDL		Unmodified, non-immobilized proteins	Carbonic anhydrase II, BRD4 (BD1 and BD2), AChE, and XIAP	2 or 3	260 × 260 for 2-BB library, 242 × 260 × 260 for 3-BB library	67 600 and 17 576–one million	45
PNA-based dynamic combinatorial libraries (PDCLs)		Immobilized proteins	Lectins (AFL and RSL)	2	150 members with 5 linkers and 10 glycans	5000	46

full ligands *in situ*. Second, the dynamic nature of DEDLs has the advantage of amplifying strong binders from a large excess of background, which may lead to better signal-to-noise ratios and a lower incidence of false positives than static libraries. However, this point has only been tested with model libraries,^{41,42} and it remains to be verified with large, chemically diverse libraries, especially at the scale of typical DELs.¹⁶⁰ Third, DCL is a thermodynamically controlled system. Adding the target protein induces a shift of the equilibrium to the point of the lowest free-energy position collectively for all compounds; thus, it is possible that a DEDL selection enriches a large number of “mediocre” ligands, whereas the enrichment of the most potent binders might be obscured. This potential issue may be addressed by using kinetic target-guided synthesis (KTGS), in which the protein templates the irreversible reaction between the fragments.¹⁶¹ Although it would not be a dynamic library *per se*, this strategy may be an alternative to DEDL for identifying the best binders from large fragment libraries. Finally, the canonical duplex architecture limits DEDLs to two sets of fragments. Although a triplex-display library was proposed by Neri and co-workers,³² it has not been practically implemented yet. Such a 3-dimensional library would boost the diversity to a level comparable to regular DELs, but it also presents more challenges in selection decoding and fragment

linking, which need to be carefully addressed in future methodology development.

Author contributions

All authors contributed to writing and editing the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work is supported by the Shandong Provincial Natural Science Foundation, China (ZR2021QB152), Faculty start-up funds of Jining Medical University, the college students' Innovative Entrepreneurial Training Plan Program of Jining Medical University (S201910443002), by the Shenzhen Bay Laboratory, Shenzhen, China (SZBL2020090501008), the Research Grants Council of Hong Kong SAR, China (AoE/P-705/16, 17301118, 17111319, 17303220, 17300321, and C7005-20G), and the NSFC of China (21877093 and 91953119). The authors acknowledge the support from “Laboratory for Synthetic



Chemistry and Chemical Biology” under the Health@InnoHK Program by the Innovation and Technology Commission, Hong Kong SAR, China.

Notes and references

- R. Macarron, M. N. Banks, D. Bojanic, D. J. Burns, D. A. Cirovic, T. Garyantes, D. V. Green, R. P. Hertzberg, W. P. Janzen, J. W. Paslay, U. Schopfer and G. S. Sittampalam, *Nat. Rev. Drug Discovery*, 2011, **10**, 188–195.
- D. Conole, J. H. Hunter and M. J. Waring, *Future Med. Chem.*, 2021, **13**, 173–191.
- A. L. Satz, L. Kuai and X. Peng, *Bioorg. Med. Chem. Lett.*, 2021, **39**, 127851.
- D. T. Flood, C. Kingston, J. C. Vantourout, P. E. Dawson and P. S. Baran, *Isr. J. Chem.*, 2020, **60**, 1–14.
- V. B. K. Kunig, M. Potowski, M. Klika Skopic and A. Brunschweiler, *ChemMedChem*, 2021, **16**, 1048–1062.
- K. Götte, S. Chines and A. Brunschweiler, *Tetrahedron Lett.*, 2020, **61**, 151889.
- P. R. Fitzgerald and B. M. Paegel, *Chem. Rev.*, 2021, **121**, 7155–7177.
- Y. Huang and X. Li, *ChemBioChem*, 2021, **22**, 2384–2397.
- T. Kodadek, N. G. Paciaroni, M. Balzarini and P. Dickson, *Chem. Commun.*, 2019, **55**, 13330–13341.
- Y. Song and X. Li, *Acc. Chem. Res.*, 2021, **54**, 3491–3503.
- M. Song and G. T. Hwang, *J. Med. Chem.*, 2020, **63**, 6578–6599.
- DyNABind; <https://www.sigmaaldrich.com/>.
- <https://www.hitgen.com/en/capabilities-details-22.html>.
- S. Patel, S. O. Badir and G. A. Molander, *Trends Chem.*, 2021, **3**, 161–175.
- P. Dickson and T. Kodadek, *Org. Biomol. Chem.*, 2019, **17**, 4676–4688.
- D. T. Flood, C. Kingston, J. C. Vantourout, P. E. Dawson and P. S. Baran, *Isr. J. Chem.*, 2020, **60**, 268–280.
- C. C. Arico-Muendel, *MedChemComm*, 2016, **7**, 1898–1909.
- S. L. Belyanskaya, Y. Ding, J. F. Callahan, A. L. Lazaar and D. I. Israel, *ChemBioChem*, 2017, **18**, 837–842.
- P. A. Harris, S. B. Berger, J. U. Jeong, R. Nagilla, D. Bandyopadhyay, N. Campobasso, C. A. Capriotti, J. A. Cox, L. Dare, X. Dong, P. M. Eidam, J. N. Finger, S. J. Hoffman, J. Kang, V. Kasparcova, B. W. King, R. Lehr, Y. Lan, L. K. Leister, J. D. Lich, T. T. MacDonald, N. A. Miller, M. T. Ouellette, C. S. Pao, A. Rahman, M. A. Reilly, A. R. Rendina, E. J. Rivera, M. C. Schaeffer, C. A. Schon, R. R. Singhaus, H. H. Sun, B. A. Swift, R. D. Totoritis, A. Vossenkamper, P. Ward, D. D. Wisnoski, D. Zhang, R. W. Marquis, P. J. Gough and J. Bertin, *J. Med. Chem.*, 2017, **60**, 1247–1261.
- J. W. Cuzzo, M. A. Clark, A. D. Keefe, A. Kohlmann, M. Mulvihill, H. Ni, L. M. Renzetti, D. I. Resnicow, F. Ruebsam, E. A. Sigel, H. A. Thomson, C. Wang, Z. Xie and Y. Zhang, *J. Med. Chem.*, 2020, **63**, 7840–7856.
- S. Brenner and R. A. Lerner, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 5381–5383.
- J. Nielsen, S. Brenner and K. D. Janda, *J. Am. Chem. Soc.*, 1993, **115**, 9812–9813.
- M. C. Needels, D. G. Jones, E. H. Tate, G. L. Heinkel, L. M. Kochersperger, W. J. Dower, R. W. Barrett and M. A. Gallop, *Proc. Natl. Acad. Sci. U. S. A.*, 1993, **90**, 10700–10704.
- A. L. Hackler, F. G. FitzGerald, V. Q. Dang, A. L. Satz and B. M. Paegel, *ACS Comb. Sci.*, 2020, **22**, 25–34.
- A. B. MacConnell, A. K. Price and B. M. Paegel, *ACS Comb. Sci.*, 2017, **19**, 181–192.
- W. G. Cochrane, M. L. Malone, V. Q. Dang, V. Cavett, A. L. Satz and B. M. Paegel, *ACS Comb. Sci.*, 2019, **21**, 425–435.
- K. R. Mendes, M. L. Malone, J. M. Ndungu, I. Saponitsky-Kroyter, V. J. Cavett, P. J. McEnaney, A. B. MacConnell, T. M. Doran, K. Ronacher, K. Stanley, O. Utset, G. Walzl, B. M. Paegel and T. Kodadek, *ACS Chem. Biol.*, 2017, **12**, 234–243.
- M. H. Shin, K. J. Lee and H. S. Lim, *Bioconjugate Chem.*, 2019, **30**, 2931–2938.
- A. Roy, E. Koesema and T. J. Kodadek, *Angew. Chem., Int. Ed.*, 2021, **60**, 11983–11990.
- A. L. Satz, L. Kuai and X. Peng, *Bioorg. Med. Chem. Lett.*, 2021, **39**, 127851.
- P. Dickson and T. Kodadek, *Org. Biomol. Chem.*, 2019, **17**, 4676–4688.
- S. Melkko, J. Scheuermann, C. E. Dumelin and D. Neri, *Nat. Biotechnol.*, 2004, **22**, 568–574.
- Z. J. Gartner, N. T. Brian, R. Grubina, J. B. Doyon, T. M. Snyder and D. R. Liu, *Science*, 2004, **305**, 1601–1605.
- D. R. Halpin and P. B. Harbury, *PLoS Biol.*, 2004, **2**, 1015–1021.
- F. Debaene, L. Mejias, J. L. Harris and N. Winssinger, *Tetrahedron*, 2004, **60**, 8677–8690.
- M. A. Clark, R. A. Acharya, C. C. Arico-Muendel, S. L. Belyanskaya, D. R. Benjamin, N. R. Carlson, P. A. Centrella, C. H. Chiu, S. P. Creaser, J. W. Cuzzo, C. P. Davie, Y. Ding, G. J. Franklin, K. D. Franzen, M. L. Gefter, S. P. Hale, N. J. V. Hansen, D. I. Israel, J. W. Jiang, M. J. Kavarana, M. S. Kelley, C. S. Kollmann, F. Li, K. Lind, S. Mataruse, P. F. Medeiros, J. A. Messer, P. Myers, H. O’Keefe, M. C. Oliff, C. E. Rise, A. L. Satz, S. R. Skinner, J. L. Svendsen, L. J. Tang, K. van Vloten, R. W. Wagner, G. Yao, B. G. Zhao and B. A. Morgan, *Nat. Chem. Biol.*, 2009, **5**, 647–654.
- M. Wichert, N. Krall, W. Decurtins, R. M. Franzini, F. Pretto, P. Schneider, D. Neri and J. Scheuermann, *Nat. Chem.*, 2015, **7**, 241–249.
- J. P. Daguer, C. Zambaldo, M. Ciobanu, P. Morieux, S. Barluenga and N. Winssinger, *Chem. Sci.*, 2015, **6**, 739–744.
- J. P. Daguer, M. Ciobanu, S. Alvarez, S. Barluenga and N. Winssinger, *Chem. Sci.*, 2011, **2**, 625–632.
- S. Barluenga, C. Zambaldo, H. A. Ioannidou, M. Ciobanu, P. Morieux, J. P. Daguer and N. Winssinger, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 1080–1085.
- F. V. Reddavid, W. Lin, S. Lehnert and Y. Zhang, *Angew. Chem., Int. Ed.*, 2015, **54**, 7924–7928.



- 42 F. V. Reddavid, M. Cui, W. Lin, N. Fu, S. Heiden, H. Andrade, M. Thompson and Y. Zhang, *Chem. Commun.*, 2019, **55**, 3753–3756.
- 43 G. Li, W. Zheng, Z. Chen, Y. Zhou, Y. Liu, J. Yang, Y. Huang and X. Li, *Chem. Sci.*, 2015, **6**, 7097–7104.
- 44 Y. Zhou, C. Li, J. Peng, L. Xie, L. Meng, Q. Li, J. Zhang, X. D. Li, X. Li, X. Huang and X. Li, *J. Am. Chem. Soc.*, 2018, **140**, 15859–15867.
- 45 Y. Deng, J. Peng, F. Xiong, Y. Song, Y. Zhou, J. Zhang, F. S. Lam, C. Xie, W. Shen, Y. Huang, L. Meng and X. Li, *Angew. Chem., Int. Ed.*, 2020, **59**, 14965–14972.
- 46 L. Farrera-Soler, J. P. Daguier, P. Raunft, S. Barluenga, A. Imberty and N. Winssinger, *Bioorg. Med. Chem.*, 2020, **28**, 115458.
- 47 T. Machida, A. Novoa, E. Gillon, S. Zheng, J. Claudinon, T. Eierhoff, A. Imberty, W. Romer and N. Winssinger, *Angew. Chem., Int. Ed.*, 2017, **56**, 6762–6766.
- 48 E. Lenci, L. Baldini and A. Trabocchi, *Bioorg. Med. Chem.*, 2021, **41**, 116218.
- 49 C. J. Gerry, M. J. Wawer, P. A. Clemons and S. L. Schreiber, *J. Am. Chem. Soc.*, 2019, **141**, 10225–10235.
- 50 L. Guasch, M. Reutlinger, D. Stoffler and M. Wichert, *Chimia*, 2021, **75**, 105–107.
- 51 A. Martin, C. A. Nicolaou and M. A. Toledo, *Commun. Chem.*, 2020, **3**, 127.
- 52 K. McCloskey, E. A. Sigel, S. Kearnes, L. Xue, X. Tian, D. Moccia, D. Gikunju, S. Bazzaz, B. Chan, M. A. Clark, J. W. Cuozzo, M. A. Guie, J. P. Guilinger, C. Huguet, C. D. Hupp, A. D. Keefe, C. J. Mulhern, Y. Zhang and P. Riley, *J. Med. Chem.*, 2020, **63**, 8857–8866.
- 53 A. B. MacConnell, P. J. McEnaney, V. J. Cavett and B. M. Paegel, *ACS Comb. Sci.*, 2015, **17**, 518–534.
- 54 J. Bobers, M. K. Skopic, R. Dinter, P. Sakthithasan, L. Neukirch, C. Gramse, R. Weberskirch, A. Brunschweiler and N. Kockmann, *ACS Comb. Sci.*, 2020, **22**, 101–108.
- 55 J. Castanon, J. P. Roman, T. C. Jessop, J. de Blas and R. Haro, *SLAS Discovery*, 2018, **23**, 387–396.
- 56 S. Chamakuri, S. Lu, M. N. Ucisik, K. M. Bohren, Y. C. Chen, H. C. Du, J. C. Faver, R. Jimmidi, F. Li, J. Y. Li, P. Nyshadham, S. S. Palmer, J. Pollet, X. Qin, S. E. Ronca, B. Sankaran, K. L. Sharma, Z. Tan, L. Versteeg, Z. Yu, M. M. Matzuk, T. Palzkill and D. W. Young, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2111172118.
- 57 W. Decurtins, M. Wichert, R. M. Franzini, F. Buller, M. A. Stravs, Y. Zhang, D. Neri and J. Scheuermann, *Nat. Protoc.*, 2016, **11**, 764–780.
- 58 Y. Li, G. Zimmermann, J. Scheuermann and D. Neri, *ChemBioChem*, 2017, **18**, 848–852.
- 59 A. Sannino, E. Gabriele, M. Bigatti, S. Mulatto, J. Piazzi, J. Scheuermann, D. Neri, E. J. Donckele and F. Samain, *ChemBioChem*, 2019, **20**, 955–962.
- 60 K. E. Denton and C. J. Krusemark, *MedChemComm*, 2016, **7**, 2020–2027.
- 61 K. E. Denton, S. Wang, M. C. Gignac, N. Milosevich, F. Hof, E. C. Dykhuizen and C. J. Krusemark, *SLAS Discovery*, 2018, **23**, 417–428.
- 62 A. Sannino, A. Gironda-Martinez, E. M. D. Gorre, L. Prati, J. Piazzi, J. Scheuermann, D. Neri, E. J. Donckele and F. Samain, *ACS Comb. Sci.*, 2020, **22**, 204–212.
- 63 Q. Chen, X. Cheng, L. Zhang, X. Li, P. Chen, J. Liu, L. Zhang, H. Wei, Z. Li and D. Dou, *SLAS Discovery*, 2020, **25**, 523–529.
- 64 S. Otto, R. L. Furlan and J. K. Sanders, *Drug Discovery Today*, 2002, **7**, 117–125.
- 65 O. Ramstrom and J. M. Lehn, *Nat. Rev. Drug Discovery*, 2002, **1**, 26–36.
- 66 P. T. Corbett, J. Leclaire, L. Vial, K. R. West, J. L. Wietor, J. K. Sanders and S. Otto, *Chem. Rev.*, 2006, **106**, 3652–3711.
- 67 J. M. Lehn, *Chem. Soc. Rev.*, 2007, **36**, 151–160.
- 68 S. Ladame, *Org. Biomol. Chem.*, 2008, **6**, 219–226.
- 69 M. F. Schmidt and J. Rademann, *Trends Biotechnol.*, 2009, **27**, 512–521.
- 70 R. A. Hunt and S. Otto, *Chem. Commun.*, 2011, **47**, 847–858.
- 71 F. B. Cougnon and J. K. Sanders, *Acc. Chem. Res.*, 2012, **45**, 2211–2221.
- 72 Y. Jin, C. Yu, R. J. Denman and W. Zhang, *Chem. Soc. Rev.*, 2013, **42**, 6634–6654.
- 73 J. Li, P. Nowak and S. Otto, *J. Am. Chem. Soc.*, 2013, **135**, 9222–9239.
- 74 A. Herrmann, *Chem. Soc. Rev.*, 2014, **43**, 1899–1933.
- 75 Q. Ji, R. C. Lirag and O. S. Miljanic, *Chem. Soc. Rev.*, 2014, **43**, 1873–1884.
- 76 M. Mondal and A. K. Hirsch, *Chem. Soc. Rev.*, 2015, **44**, 2455–2488.
- 77 J. M. Lehn, *Angew. Chem., Int. Ed.*, 2015, **54**, 3276–3289.
- 78 A. Canal-Martin and R. Perez-Fernandez, *ACS Omega*, 2020, **5**, 26307–26315.
- 79 D. A. Erlanson, A. C. Braisted, D. R. Raphael, M. Randal, R. M. Stroud, E. M. Gordon and J. A. Wells, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 9367–9372.
- 80 D. A. Erlanson, J. W. Lam, C. Wiesmann, T. N. Luong, R. L. Simmons, W. L. DeLano, I. C. Choong, M. T. Burdett, W. M. Flanagan, D. Lee, E. M. Gordon and T. O'Brien, *Nat. Biotechnol.*, 2003, **21**, 308–314.
- 81 B. R. McNaughton and B. L. Miller, *Org. Lett.*, 2006, **8**, 1803–1806.
- 82 R. F. Ludlow and S. Otto, *J. Am. Chem. Soc.*, 2008, **130**, 12218–12219.
- 83 B. R. McNaughton, P. C. Gareiss and B. L. Miller, *J. Am. Chem. Soc.*, 2007, **129**, 11306–11307.
- 84 P. C. Gareiss, K. Sobczak, B. R. McNaughton, P. B. Palde, C. A. Thornton and B. L. Miller, *J. Am. Chem. Soc.*, 2008, **130**, 16254–16261.
- 85 D. A. Erlanson, S. W. Fesik, R. E. Hubbard, W. Jahnke and H. Jhoti, *Nat. Rev. Drug Discovery*, 2016, **15**, 605–619.
- 86 R. Huang and I. K. Leung, *Molecules*, 2016, **21**, 910.
- 87 V. T. Bhat, A. M. Caniard, T. Luksch, R. Brenk, D. J. Campopiano and M. F. Greaney, *Nat. Chem.*, 2010, **2**, 490–497.
- 88 I. Huc and J. M. Lehn, *Proc. Natl. Acad. Sci. U. S. A.*, 1997, **94**, 2106–2110.
- 89 S. Zameo, B. Vauzeilles and J. M. Beau, *Angew. Chem., Int. Ed.*, 2005, **44**, 965–969.



- 90 B. Shi, R. Stevenson, D. J. Campopiano and M. F. Greaney, *J. Am. Chem. Soc.*, 2006, **128**, 8459–8467.
- 91 O. Ramström and J. M. Lehn, *ChemBioChem*, 2000, **1**, 41–48.
- 92 M. Demetriades, I. K. Leung, R. Chowdhury, M. C. Chan, M. A. McDonough, K. K. Yeoh, Y. M. Tian, T. D. Claridge, P. J. Ratcliffe and E. C. Woon, *Angew. Chem., Int. Ed.*, 2012, **51**, 6672–6675.
- 93 R. Larsson, Z. Pei and O. Ramstrom, *Angew. Chem., Int. Ed.*, 2004, **43**, 3716–3718.
- 94 S. M. Voshell, S. J. Lee and M. R. Gagne, *J. Am. Chem. Soc.*, 2006, **128**, 12422–12423.
- 95 A. Buryak and K. Severin, *Angew. Chem., Int. Ed.*, 2005, **44**, 7935–7938.
- 96 F. V. Reddavid, M. Thompson, L. Mannocci and Y. X. Zhang, *Aldrichimica Acta*, 2019, **52**, 63–74.
- 97 S. Melkko, Y. Zhang, C. E. Dumelin, J. Scheuermann and D. Neri, *Angew. Chem., Int. Ed.*, 2007, **46**, 4671–4674.
- 98 J. Scheuermann, C. E. Dumelin, S. Melkko, Y. X. Zhang, L. Mannocci, M. Jaggi, J. Sobek and D. Neri, *Bioconjugate Chem.*, 2008, **19**, 778–785.
- 99 G. Zimmermann, U. Rieder, D. Bajic, S. Vanetti, A. Chaikuad, S. Knapp, J. Scheuermann, M. Mattarella and D. Neri, *Chem. – Eur. J.*, 2017, **23**, 8152–8155.
- 100 M. Catalano, M. Moroglu, P. Balbi, F. Mazzieri, J. Clayton, K. H. Andrews, M. Bigatti, J. Scheuermann, S. J. Conway and D. Neri, *ChemMedChem*, 2020, **15**, 1752–1756.
- 101 S. Oehler, M. Catalano, I. Scapozza, M. Bigatti, G. Bassi, N. Favalli, M. R. Mortensen, F. Samain, J. Scheuermann and D. Neri, *Chem. – Eur. J.*, 2021, **27**, 8985–8993.
- 102 S. Oehler, L. Plais, G. Bassi, D. Neri and J. Scheuermann, *Chem. Commun.*, 2021, **57**, 12289–12292.
- 103 M. Catalano, G. Bassi, G. Rotondi, L. Khettabi, M. Dichiaro, P. Murer, J. Scheuermann, M. Soler-Lopez and D. Neri, *RSC Med. Chem.*, 2021, **12**, 363–369.
- 104 J. Scheuermann and D. Neri, *Curr. Opin. Chem. Biol.*, 2015, **26**, 99–103.
- 105 J. C. Faver, K. Riehle, D. R. Lancia, Jr., J. B. J. Milbank, C. S. Kollmann, N. Simmons, Z. Yu and M. M. Matzuk, *ACS Comb. Sci.*, 2019, **21**, 75–82.
- 106 P. Komar and M. Kalinic, *ACS Comb. Sci.*, 2020, **22**, 410–421.
- 107 L. Kuai, T. O’Keeffe and C. Arico-Muendel, *SLAS Discovery*, 2018, **23**, 405–416.
- 108 N. Winssinger and J. L. Harris, *Expert Rev. Proteomics*, 2005, **2**, 937–947.
- 109 Z. L. Pianowski and N. Winssinger, *Chem. Soc. Rev.*, 2008, **37**, 1330–1336.
- 110 K. K. Sadhu and N. Winssinger, *Chimia*, 2013, **67**, 905–909.
- 111 J. L. Harris and N. Winssinger, *Chem. – Eur. J.*, 2005, **11**, 6792–6801.
- 112 S. Barluenga and N. Winssinger, *Acc. Chem. Res.*, 2015, **48**, 1319–1331.
- 113 C. Zambaldo, S. Barluenga and N. Winssinger, *Curr. Opin. Chem. Biol.*, 2015, **26**, 8–15.
- 114 M. Ciobanu, K. T. Huang, J. P. Dagher, S. Barluenga, O. Chaloin, E. Schaeffer, C. G. Mueller, D. A. Mitchell and N. Winssinger, *Chem. Commun.*, 2011, **47**, 9321–9323.
- 115 J. Scheuermann, C. E. Dumelin, S. Melkko and D. Neri, *J. Biotechnol.*, 2006, **126**, 568–581.
- 116 S. Melkko, C. E. Dumelin, J. Scheuermann and D. Neri, *Drug Discovery Today*, 2007, **12**, 465–471.
- 117 J. Cai, B. A. Rosenzweig and A. D. Hamilton, *Chem. – Eur. J.*, 2009, **15**, 328–332.
- 118 D. M. Tagore, K. I. Sprinz, S. Fletcher, J. Jayawickramarajah and A. D. Hamilton, *Angew. Chem., Int. Ed.*, 2007, **46**, 223–225.
- 119 D. Margulies and A. D. Hamilton, *J. Am. Chem. Soc.*, 2009, **131**, 9142–9143.
- 120 D. Margulies and A. D. Hamilton, *Angew. Chem., Int. Ed.*, 2009, **48**, 1771–1774.
- 121 J. Cai, E. M. Shapiro and A. D. Hamilton, *Bioconjugate Chem.*, 2009, **20**, 205–208.
- 122 B. A. Rosenzweig, N. T. Ross, D. M. Tagore, J. Jayawickramarajah, I. Saraogi and A. D. Hamilton, *J. Am. Chem. Soc.*, 2009, **131**, 5020–5021.
- 123 K. I. Sprinz, D. M. Tagore and A. D. Hamilton, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 3908–3911.
- 124 S. Grunzner, F. V. Reddavid, C. Steinfelder, M. Cui, M. Busek, U. Klotzbach, Y. Zhang and F. Sonntag, *Microfluidics, Biomems, and Medical Microsystems XV*, 2017, 10061.
- 125 P. Zhao, Z. Chen, Y. Li, D. Sun, Y. Gao, Y. Huang and X. Li, *Angew. Chem., Int. Ed.*, 2014, **53**, 10056–10059.
- 126 B. Shi and M. F. Greaney, *Chem. Commun.*, 2005, 886–888.
- 127 S. Ladame, A. M. Whitney and S. Balasubramanian, *Angew. Chem., Int. Ed.*, 2005, **44**, 5736–5739.
- 128 L. M. McGregor, T. Jain and D. R. Liu, *J. Am. Chem. Soc.*, 2014, **136**, 3264–3270.
- 129 L. M. McGregor, D. J. Gorin, C. E. Dumelin and D. R. Liu, *J. Am. Chem. Soc.*, 2010, **132**, 15522–15524.
- 130 M. Mondal, N. Radeva, H. Koster, A. Park, C. Potamitis, M. Zervou, G. Klebe and A. K. Hirsch, *Angew. Chem., Int. Ed.*, 2014, **53**, 3259–3263.
- 131 M. Demetriades, I. K. H. Leung, R. Chowdhury, M. C. Chan, M. A. McDonough, K. K. Yeoh, Y.-M. Tian, T. D. W. Claridge, P. J. Ratcliffe, E. C. Y. Woon and C. J. Schofield, *Angew. Chem., Int. Ed.*, 2012, **51**, 6672–6675.
- 132 D. E. Scott, G. J. Dawes, M. Ando, C. Abell and A. Ciulli, *ChemBioChem*, 2009, **10**, 2772–2779.
- 133 H. Kashida, T. Doi, T. Sakakibara, T. Hayashi and H. Asanuma, *J. Am. Chem. Soc.*, 2013, **135**, 7960–7966.
- 134 A. Litovchick, M. A. Clark and A. D. Keefe, *Artif DNA PNA XNA*, 2014, **5**, e27896.
- 135 Y. Zhou, W. Shen, J. Peng, Y. Deng and X. Li, *Bioorg. Med. Chem.*, 2021, **45**, 116328.
- 136 Y. Zhou, J. Peng, W. Shen and X. Li, *Biochem. Biophys. Res. Commun.*, 2020, **533**, 215–222.
- 137 D. Neri and R. A. Lerner, *Annu. Rev. Biochem.*, 2018, **87**, 479–502.
- 138 C. W. Murray and D. C. Rees, *Nat. Chem.*, 2009, **1**, 187–192.
- 139 D. A. Erlanson, *Top. Curr. Chem.*, 2012, **317**, 1–32.
- 140 D. A. Erlanson, J. A. Wells and A. C. Braisted, *Annu. Rev. Biophys. Biomol. Struct.*, 2004, **33**, 199–223.
- 141 R. H. Nonoo, A. Armstrong and D. J. Mann, *ChemMedChem*, 2012, **7**, 2082–2086.



- 142 W. P. Jencks, *Proc. Natl. Acad. Sci. U. S. A.*, 1981, **78**, 4046–4050.
- 143 G. G. Ferenczy and G. M. Keseru, *MedChemComm*, 2016, **7**, 332–337.
- 144 G. G. Ferenczy and G. M. Keseru, *J. Chem. Inf. Model.*, 2012, **52**, 1039–1045.
- 145 S. Melkko, C. E. Dumelin, J. Scheuermann and D. Neri, *Chem. Biol.*, 2006, **13**, 225–231.
- 146 M. Bigatti, A. Dal Corso, S. Vanetti, S. Cazzamalli, U. Rieder, J. Scheuermann, D. Neri and F. Sladojevich, *ChemMedChem*, 2017, **12**, 1748–1752.
- 147 S. Chung, J. B. Parker, M. Bianchet, L. M. Amzel and J. T. Stivers, *Nat. Chem. Biol.*, 2009, **5**, 407–413.
- 148 A. W. Hung, H. L. Silvestre, S. Wen, A. Ciulli, T. L. Blundell and C. Abell, *Angew. Chem., Int. Ed.*, 2009, **48**, 8452–8456.
- 149 G. Zimmermann, U. Rieder, D. Bajic, S. Vanetti, A. Chaikuad, S. Knapp, J. Scheuermann, M. Mattarella and D. Neri, *Chem. – Eur. J.*, 2017, **23**, 8152–8155.
- 150 F. Abendroth, A. Bujotzek, M. Shan, R. Haag, M. Weber and O. Seitz, *Angew. Chem., Int. Ed.*, 2011, **50**, 8592–8596.
- 151 M. Bigatti, A. Dal Corso, S. Vanetti, S. Cazzamalli, U. Rieder, J. Scheuermann, D. Neri and F. Sladojevich, *ChemMedChem*, 2017, **12**, 1748–1752.
- 152 M. Jaegle, E. L. Wong, C. Tauber, E. Nawrotzky, C. Arkona and J. Rademann, *Angew. Chem., Int. Ed.*, 2017, **56**, 7358–7378.
- 153 C. L. Tung, C. T. Wong, E. Y. Fung and X. Li, *Org. Lett.*, 2016, **18**, 2600–2603.
- 154 R. M. Franzini, T. Ekblad, N. Zhong, M. Wichert, W. Decurtins, A. Nauer, M. Zimmermann, F. Samain, J. Scheuermann, P. J. Brown, J. Hall, S. Graslund, H. Schuler and D. Neri, *Angew. Chem., Int. Ed.*, 2015, **54**, 3927–3931.
- 155 F. Diezmann and O. Seitz, *Chem. Soc. Rev.*, 2011, **40**, 5789–5801.
- 156 B. R. Vummidi, L. Farrera-Soler, J. P. Dagher, M. Dockerill, S. Barluenga and N. Winssinger, *Nat. Chem.*, 2021, 1–12.
- 157 M. T. Cancilla, M. M. He, N. Viswanathan, R. L. Simmons, M. Taylor, A. D. Fung, K. Cao and D. A. Erlanson, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 3978–3981.
- 158 L. K. Petersen, A. B. Christensen, J. Andersen, C. G. Folkesson, O. Kristensen, C. Andersen, A. Alzu, F. A. Slok, P. Blakskjaer, D. Madsen, C. Azevedo, I. Micco and N. J. V. Hansen, *J. Am. Chem. Soc.*, 2021, **143**, 2751–2756.
- 159 C. O. Mellet, J. F. Nierengarten and J. M. G. Fernandez, *J. Mater. Chem. B*, 2017, **5**, 6428–6436.
- 160 A. L. Satz, R. Hochstrasser and A. C. Petersen, *ACS Comb. Sci.*, 2017, **19**, 234–238.
- 161 D. Bosc, V. Camberlein, R. Gealageas, O. Castillo-Aguilera, B. Deprez and R. Deprez-Poulain, *J. Med. Chem.*, 2020, **63**, 3817–3833.

